齐拉西酮治疗32例女性精神分裂症患者不良反应观察

目的 探讨齐拉西酮对女性精神分裂症患者的安全性.方法 收集32例女性精神分裂症患者,给予齐拉西酮治疗观察6周,分别于治疗前及治疗后第2、4、6周末进行实验室及心电图检查,探讨该药对女性精神分裂症患者血脂、血糖、体重及心电图的影响.结果 治疗后精神分裂症患者甘油三酯、胆固醇及体重均较治疗前有明显升高,差异具有统计学意义（P＜0.05）;治疗4周后精神分裂症患者QT及QTC间期均较治疗前有显著延长,差异具有统计学意义（P＜0.05）.结论 齐拉西酮对女性精神分裂症患者血脂、体重及QT间期影响较大,对血糖影响较小.

The observation of adverse reactions of Ziprasidone in the treatment of 32 cases of female schizophrenia

Objective To discuss the safety of Ziprasidone in female schizophrenia patients. Methods 32 cases of female schizophrenia were treated with Ziprasidonc for 6 weeks. Laboratory examination and ECG examination were carried out before and 2, 4, 6 weeks after treatment. Investigated the influence of Ziprasidone on lipid, blood glncose, body weight and ECG in female schizophrenia patients. Results The levels of triglyceride, cholesterol and body weight of ti~male schizophrenia patients after treatment significantly rose than those before treatment, with statistical significant dift）rences （P 〈 0.05）; QT and QTC interval 4 weeks after trealment significantly prolonged, with statistical significant differences （P 〈 0.05）. Conclusion Ziprasidone has influence on senlm lipid, body weight and QT interval in female schizophrenic patients, but not on blood ulucose.